Interactions between Bosentan and Danazol

Danazol has a major potential interaction with Abnormal Uterine Bleeding.

The use of danazol is contraindicated in patients with undiagnosed, abnormal genital bleeding. Patients should be evaluated to ensure that neoplastic lesions are not present. Alterations of menstruation including irregular cycles, amenorrhea, breakthrough bleeding, and spotting have occurred during danazol therapy.

Bosentan has a moderate potential interaction with Anemia.

Clinical studies have shown that most endothelin receptor antagonists decrease hemoglobin concentration and hematocrit levels. There are some postmarketing reports of anemia cases which needed blood transfusion. Hemoglobin and hematocrit levels should be measured prior to treatment initiation and should be monitored periodically thereafter. Initiation of therapy is not recommended in patients with clinically significant anemia.

Danazol has a major potential interaction with Bleeding Disorder.

Danazol is contraindicated in patients with thrombosis or thromboembolic disease or a history of such events. Thromboembolism, thrombotic and thrombophlebitic events, including fatal strokes, have occurred during danazol therapy. Hematuria, menstrual spotting and thrombocytopenia have also occurred. Additionally, therapy with danazol should be administered cautiously in patients with or predisposed to bleeding/clotting disorders.

Danazol has a major potential interaction with Diabetes Mellitus.

Danazol possess androgenic activity that can result in salt and water retention. Danazol is eliminated by the kidney, and its use is contraindicated in patients with severe renal dysfunction. It should also be administered cautiously in patients adversely affected by volume overload, such as patients suffering from epilepsy, diabetes mellitus, migraine, cardiac or renal dysfunction, polycythemia and hypertension. These patients will require careful observation.

Danazol has a major potential interaction with Fluid Retention.

Danazol possess androgenic activity that can result in salt and water retention. Danazol is eliminated by the kidney, and its use is contraindicated in patients with severe renal dysfunction. It should also be administered cautiously in patients adversely affected by volume overload, such as patients suffering from epilepsy, diabetes mellitus, migraine, cardiac or renal dysfunction, polycythemia and hypertension. These patients will require careful observation.

Danazol has a major potential interaction with Heart Disease.

Danazol is contraindicated in patients with marked impaired cardiac function.

Danazol has a major potential interaction with Heart Failure.

Danazol possess androgenic activity that can result in salt and water retention. Danazol is eliminated by the kidney, and its use is contraindicated in patients with severe renal dysfunction. It should also be administered cautiously in patients adversely affected by volume overload, such as patients suffering from epilepsy, diabetes mellitus, migraine, cardiac or renal dysfunction, polycythemia and hypertension. These patients will require careful observation.

Bosentan has a moderate potential interaction with Heart Failure.

Peripheral edema and fluid retention are known clinical consequences of pulmonary hypertension and also known effects of endothelin receptor antagonists. Caution and monitoring is recommended if these agents are used in patients with underlying left ventricular dysfunction or underlying heart failure, as they have an increased risk for developing significant fluid retention that may need treatment or require discontinuation.

Danazol has a major potential interaction with High Blood Pressure.

Danazol possess androgenic activity that can result in salt and water retention. Danazol is eliminated by the kidney, and its use is contraindicated in patients with severe renal dysfunction. It should also be administered cautiously in patients adversely affected by volume overload, such as patients suffering from epilepsy, diabetes mellitus, migraine, cardiac or renal dysfunction, polycythemia and hypertension. These patients will require careful observation.

Danazol has a major potential interaction with History, Thrombotic/Thromboembolic Disorder.

Danazol is contraindicated in patients with thrombosis or thromboembolic disease or a history of such events. Thromboembolism, thrombotic and thrombophlebitic events, including fatal strokes, have occurred during danazol therapy. Hematuria, menstrual spotting and thrombocytopenia have also occurred. Additionally, therapy with danazol should be administered cautiously in patients with or predisposed to bleeding/clotting disorders.

Bosentan has a major potential interaction with Liver Disease.

Endothelin receptor antagonists (ERAs) have been associated with aminotransferase elevations, hepatotoxicity, and cases of liver failure. Hepatic function should be assessed before treatment initiation and closely monitored during treatment. Therapy should be discontinued if aminotransferase elevations are accompanied by increases in bilirubin, or clinical symptoms of hepatotoxicity such as nausea, vomiting, fever, abdominal pain or jaundice. Treatment should be avoided in patients with elevated aminotransferases at baseline as monitoring for hepatotoxicity may be more difficult. In general, the use of ERAs is not recommended for patients with moderate to severe hepatic impairment.

Danazol has a major potential interaction with Liver Disease.

The use of danazol is contraindicated in patients with severe hepatic impairment. Danazol is metabolized by the liver to inactive forms. Metabolic and therapeutic activity of danazol may be altered in patients with severe hepatic dysfunction. Elevated serum transaminase levels, peliosis hepatis and benign hepatic adenoma have occurred during chronic administration of danazol. Therapy with danazol should be administered cautiously in patients with or predisposed to hepatic dysfunction.

Danazol has a major potential interaction with Migraine.

Danazol possess androgenic activity that can result in salt and water retention. Danazol is eliminated by the kidney, and its use is contraindicated in patients with severe renal dysfunction. It should also be administered cautiously in patients adversely affected by volume overload, such as patients suffering from epilepsy, diabetes mellitus, migraine, cardiac or renal dysfunction, polycythemia and hypertension. These patients will require careful observation.

Danazol has a major potential interaction with Porphyria.

The use of danazol is contraindicated in patients with porphyria. Danazol can induce production of delta- aminolevulinic acid (ALA) synthetase activity resulting in porphyrin metabolism.

Danazol has a major potential interaction with Prostate Tumor, Benign.

The use of danazol is contraindicated in patients with androgen- dependent tumors.

Danazol has a major potential interaction with Pseudotumor Cerebri.

Intracranial hypertension (pseudotumor cerebri) has occurred in patients receiving danazol. Therapy with danazol should be administered cautiously in patients with or predisposed to cerebral or papilledema and/or intracranial hypertension.

Danazol has a major potential interaction with Renal Dysfunction.

Danazol possess androgenic activity that can result in salt and water retention. Danazol is eliminated by the kidney, and its use is contraindicated in patients with severe renal dysfunction. It should also be administered cautiously in patients adversely affected by volume overload, such as patients suffering from epilepsy, diabetes mellitus, migraine, cardiac or renal dysfunction, polycythemia and hypertension. These patients will require careful observation.

Danazol has a major potential interaction with Seizures.

Danazol possess androgenic activity that can result in salt and water retention. Danazol is eliminated by the kidney, and its use is contraindicated in patients with severe renal dysfunction. It should also be administered cautiously in patients adversely affected by volume overload, such as patients suffering from epilepsy, diabetes mellitus, migraine, cardiac or renal dysfunction, polycythemia and hypertension. These patients will require careful observation.

Danazol has a major potential interaction with Thrombotic/Thromboembolic Disorder.

Danazol is contraindicated in patients with thrombosis or thromboembolic disease or a history of such events. Thromboembolism, thrombotic and thrombophlebitic events, including fatal strokes, have occurred during danazol therapy. Hematuria, menstrual spotting and thrombocytopenia have also occurred. Additionally, therapy with danazol should be administered cautiously in patients with or predisposed to bleeding/clotting disorders.